Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
ImmunoMet Therapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
ImmunoMet Therapeutics

ImmunoMet Therapeutics

Series A

ImmunoMet Therapeutics: A clinical-stage biotech firm innovating oncology products to enhance patient lives.

HQ
Houston, TX, US
Founded
2015
Overview
Compare
Fundraising
Employees
Website

ImmunoMet Therapeutics is a clinical-stage biotechnology company focused on developing innovative oncology and fibrosis treatments. The company's approach centers on targeting cellular metabolism to create novel therapies for cancer patients and those with fibrotic conditions. ImmunoMet's research and development efforts aim to harness metabolic reprogramming across multiple therapeutic areas, with a particular emphasis on improving the quality of life for cancer patients.

The company's lead candidate, IM156, has entered clinical trials, with a Phase 1b study in pancreatic cancer patients recently initiated. This milestone underscores ImmunoMet's progress in translating its metabolic-based approach from laboratory research to potential clinical applications. The company's pipeline and development programs reflect its commitment to addressing unmet medical needs in oncology and fibrosis through innovative metabolic-targeted therapies.

ImmunoMet Therapeutics - Similar Companies

Imvaq Therapeutics logo

Imvaq Therapeutics

INmune Bio logo

INmune Bio

inmunebio.com

Immune-Onc Therapeutics logo

Immune-Onc Therapeutics

immuneonc.com

Immunitas Therapeutics logo

Immunitas Therapeutics

immunitastx.com

Immunome logo

Immunome

ImmunoGenesis logo

ImmunoGenesis

immunogenesis.com

IM Therapeutics logo

IM Therapeutics

imtherapeutics.com

Inimmune logo

Inimmune

inimmune.com

ImmuCision Biotherapeutics logo

ImmuCision Biotherapeutics

Imunon logo

Imunon

imunon.com

ImmunityBio logo

ImmunityBio

immunitybio.com

Imvax logo

Imvax

imvax.com

Metaclipse Therapeutics logo

Metaclipse Therapeutics

BioEclipse Therapeutics logo

BioEclipse Therapeutics

bioeclipse.com

Immunicom logo

Immunicom

immunicom.com

ImmunoMet Therapeutics - Quick Facts

Who are ImmunoMet Therapeutics' competitors?

Companies similar to ImmunoMet Therapeutics include Imvaq Therapeutics, INmune Bio, Immune-Onc Therapeutics and Immunitas Therapeutics.

When was ImmunoMet Therapeutics founded?

ImmunoMet Therapeutics was founded in 2015.

Where is ImmunoMet Therapeutics' headquarters located?

ImmunoMet Therapeutics' headquarters is located in Houston, TX, US.

When was ImmunoMet Therapeutics' last funding round?

ImmunoMet Therapeutics' most recent funding round was for $7M (USD) in February 2021.

How much has ImmunoMet Therapeutics raised to-date?

As of Feb 8, 2021, ImmunoMet Therapeutics has raised a total of $17.2M (USD).

How many employees does ImmunoMet Therapeutics have?

ImmunoMet Therapeutics has 15 employees as of Feb 4, 2024.

ImmunoMet Therapeutics - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Oncology Therapeutics
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified